The aim of the investigation was to assess the efficiency of a long-term ethylmethylhydroxypyridine succinate (EMHPS) infusion in patients with severe concomitant traumatic brain injury (TBI) by the dynamics of cerebral macrocirculation, consciousness level and state severity index.Materials and Methods. We examined two groups of patients, 25 patients in each group, with severe concomitant TBI. The 1 st group (control) patients underwent standard intensive therapy. The 2 nd group patients, in addition to standard treatment, had EMHPS infusion in a dose 100 mg/h through an infusion pump for 10 days. Using transcranial dopplerography we studied linear blood flow rate (lBFR): systolic blood velocity, diastolic blood velocity, mean blood velocity, pulsation index and resistance index, and assessed the consciousness level dynamics using Glasgow coma scale and the severity of patients' state according to APACHE II.Results. In the 1 st group patients lBFR normalized in 24, 32, 48 and 72% cases on day 3, 5 7 and 10, respectively, while in the 2 nd group patients, LBFR values normalized in 48, 60, 64 and 80% cases within the same period. When using EMHPS, the quicker consciousness recovery was reported: in 60 and 24% patients, respectively, in groups 2 and 1 by day 5; in 80 and 60% patients by day 10. In the 2 nd group patients by day 10 the severity index values according to APACHE II were 2 times less than in group 1.Conclusion. long-term (within 10 days) EMHPS infusion in a dose of 100 mg/h in patients with severe TBI contributes to more rapid normalization of lBFR parameters, consciousness recovery and the decrease of severity according to APACHE II.Key words: traumatic brain injury; ethylmethylhydroxypyridine succinate; cerebral blood flow; consciousness level; APACHE II. The application of therapeutic technologies aimed to recover the sufferers with traumatic brain injury (TBI) from shock and homeostasis is an integral part of standard intensive therapy: respiratory support; circulatory support; correction of hemostasis, arterial oxygen content, hydro-electrolytic balance and acid-base balance, metabolism; anaesthesia and sedation; antibacterial therapy; prevention of stress ulcers and thromboembolic complications; enteral and parenteral nutrition; intracranial pressure correction [1][2][3][4]. However, mortality indices remain stably high in these patients that stimulates a search for new treatment techniques [5, 6].One of them can be the application of antihypoxic and antioxidant agents to minimize the development of secondary ischemic brain injury. If blood flow is normalized in the area of "ischemic penumbra", cerebral metabolism and brain functions restore. Moreover, antihypoxic and antioxidant effects, as a rule, are not organ-specific, and have a positive effect on both: neurons, as well as cardiomyocytes, cells of the liver, kidneys, intestine, lungs [7][8][9].One of medicinal agents with a proved universal cytoprotective effect including that on the brain is ethylmethylhydroxypyridine succinate (EMHPS) [10...